Inflammatory Disease News and Research

RSS

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.

28 Jun 2010

Study finds significant loss of work productivity among women who suffer from endometriosis

The first worldwide study of the societal impact of endometriosis has found a significant loss of work productivity among those women who suffer from the condition, a researcher told the 26th annual meeting of the European Society of Human Reproduction and Embryology today (Monday). Dr. Kelechi Nnoaham, from the Department of Public Health, University of Oxford, UK, said that the results of this multi-centre study would help highlight the previously unrecognised plight of an estimated 176 million women around the world whose lives are affected by endometriosis.

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Cardio-respiratory aerobic exercise reduces joint pain in RA patients

Researchers from the University of Grenoble Medical School in France determined that cardio-respiratory aerobic exercise is safe for patients with stable rheumatoid arthritis (RA).

25 Jun 2010

Johns Hopkins School of Medicine develops RAALI for healthcare providers

The Johns Hopkins School of Medicine, the nation's leading medical school recipient of research funds from the National Institutes of Health and a recognized center for "Best Practices" by the Accreditation Council for Continuing Medical Education, discussed the development of a unique medical education initiative - the Rheumatoid Arthritis Action Lab Initiative - to give healthcare providers connectivity to much-needed information on rheumatoid arthritis.

23 Jun 2010

Ensemble Discovery announces name change to Ensemble Therapeutics Corporation

Ensemble Discovery today announced that it will begin operating as Ensemble Therapeutics Corporation to reflect the Company's progress and emerging pipeline by applying its macrocycle drug platform to develop novel therapeutics. The new name, Ensemble Therapeutics, conveys the company's leadership and advancement in developing novel macrocycle drug compounds that are small molecules with expanded therapeutic properties of large molecule biological drugs.

22 Jun 2010

Staloral 300 demonstrates efficacy in phase III study for control of asthma in China

Stallergenes S.A. announces the results of a phase III clinical trial (VO55.06) conducted in China aimed at assessing the efficacy and safety of sublingual immunotherapy (Staloral(R) mites 300) in adult patients suffering from asthma triggered by house dust mites.

21 Jun 2010

Too much tea raises the risk of rheumatoid arthritis: Study

Rheumatoid arthritis (RA) a severely debilitating inflammatory disease of the joints is on the rise worldwide. It leads to severe pain, stiffness, swelling and loss of movement of joints like knees, wrist and even fingers. RA affects women more than men. RA occurs in people who develop a rogue immune system that attacks the tissue that lines the joint cavities called the synovium leading to degeneration of the joints and the symptoms of the disease. In 1995 36.4 per 100,000 women were diagnosed with RA whereas in 2005 the number rose to 54 per 100,000 women.

20 Jun 2010

Study validates NT-proBNP as strong indicator for cardiovascular risk in arthritis patients

The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP, a protein thought to be a regulator of cardiovascular function) as a robust, non-invasive predictor of cardiovascular (CV) risk in patients with arthritis taking cyclooxygenase inhibitors has been reinforced by the results of a multinational study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

Biological mechanism associated with remission during pregnancy

During pregnancy, many women experience remission of autoimmune diseases like multiple sclerosis and uveitis. Now, scientists have described a biological mechanism responsible for changes in the immune system that helps to explain the remission.

17 Jun 2010

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).

17 Jun 2010

New data from Phase 2a trial support further development of BMS-945429/ALD518 monoclonal antibody for RA

Bristol-Myers Squibb Company and Alder Biopharmaceuticals today announced that new data from a dose-ranging Phase 2a trial support further development of BMS-945429/ALD518, an investigational monoclonal antibody directed against interleukin-6 (IL-6), as a potential treatment for rheumatoid arthritis (RA). The Phase 2a data will be presented in a scientific session on June 18, 2010, at the Annual Congress of the European League against Rheumatism (EULAR).

16 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

Monoclonal antibodies induce long-lasting, protective antiviral immune response

Monoclonal antibodies are the largest class of biotherapeutic drugs. When administered to infected organisms to blunt the propagation of pathogenic viruses, they may also induce a long-lasting and protective antiviral immune response similar to that achieved by vaccination. These results obtained in mice by the "Oncogenèse et Immunothérapie" group at the Institut de Génétique Moléculaire de Montpellier (CNRS/Universités Montpellier 1 and 2), have been published on 10 June in PLoS Pathogens.

14 Jun 2010

Alder Biopharmaceuticals reports positive data from ALD518 Phase 2a clinical trial for NSCLC

Alder Biopharmaceuticals Inc. today announced that patients with late-stage non-small cell lung cancer (NSCLC) showed improvement in cancer-related anemia and symptoms of the disease in a Phase 2a clinical trial of ALD518, a monoclonal antibody directed against interleukin-6 (IL-6).

7 Jun 2010

Mayo Clinic research reveals increase in incidence of rheumatoid arthritis in women

The incidence of rheumatoid arthritis (RA) in women has risen during the period of 1995 to 2007, according to a newly published study by researchers from the Mayo Clinic. This rise in RA follows a 4-decade period of decline and study authors speculate environmental factors such as cigarette smoking, vitamin D deficiency, and lower dose synthetic estrogens in oral contraceptives may be the source of the increase.

27 May 2010

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, "HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS," which includes coverage of Amira's AM461 DP2 receptor antagonist.

27 May 2010

Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV

Roche Diagnostics Canada announced today the launch of a new Health Canada approved clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas(R) 4800 System combines in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology.

From Roche Sequencing and Life Science 7 May 2010

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.

7 May 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Roche today announced that Health Canada has approved ACTEMRA(TM) (tocilizumab) to treat patients with rheumatoid arthritis (RA), a chronic, progressive inflammatory disease of the joints and surrounding tissues that is associated with intense pain, irreversible joint destruction and systemic complications, such as fatigue and anemia.

4 May 2010

Inflammatory Disease News and Research

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

Study finds significant loss of work productivity among women who suffer from endometriosis

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

Cardio-respiratory aerobic exercise reduces joint pain in RA patients

Johns Hopkins School of Medicine develops RAALI for healthcare providers

Ensemble Discovery announces name change to Ensemble Therapeutics Corporation

Staloral 300 demonstrates efficacy in phase III study for control of asthma in China

Too much tea raises the risk of rheumatoid arthritis: Study

Study validates NT-proBNP as strong indicator for cardiovascular risk in arthritis patients

Biological mechanism associated with remission during pregnancy

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

New data from Phase 2a trial support further development of BMS-945429/ALD518 monoclonal antibody for RA

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Monoclonal antibodies induce long-lasting, protective antiviral immune response

Alder Biopharmaceuticals reports positive data from ALD518 Phase 2a clinical trial for NSCLC

Mayo Clinic research reveals increase in incidence of rheumatoid arthritis in women

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Roche announces Health Canada approval for ACTEMRA to treat RA

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News